bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

“Fireside Chat” with Maria Zannes, CEO of bioAffinity Technologies, Inc. (NASDAQ: BIAF)

by Maria Zannes | Feb 22, 2023 | Articles, News

FEBRUARY 22, 2023 bioAffinity Technologies President and CEO Maria Zannes recently joined host Seth Farbman on his podcast From Start-Up to Stock Exchange. Listen here https://lnkd.in/g-vkTfKv to learn more about the need for early screening for lung cancer when it is...

Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes

by Dale Harrison | Dec 28, 2022 | Articles, News

Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes DECEMBER 28, 2022 As published in the The Fly By: Jessica de Sa-Mota BioAffinity focuses on the development of noninvasive, early-stage cancer diagnosis and targeted cancer treatment In an...

SA Cancer Diagnostic Company Adding Research Talent

by Dale Harrison | Dec 23, 2022 | Articles, News

SA Cancer Diagnostic Company Adding Research Talent DECEMBER 23, 2022 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies Inc. is making multiple personnel moves in an effort to...

Maria Zannes named to TEXAS 100 Influential professionals to watch in 2023

by Dale Harrison | Dec 21, 2022 | Articles, News

TEXAS 100 Influential professionals to watch in 2023 DECEMBER 21, 2022 As published in the San Antonio Business Journal By: Colin Pope – Editor, Austin Business Journal Our annual Texas 100 is a list of impactful Texans who will likely play crucial roles in the...

After going public, SA company charts next course

by Dale Harrison | Nov 29, 2022 | Articles, News

After going public, SA company charts next course NOVEMBER 29, 2022 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal Fresh off of filing its first earnings report as a publicly traded company, San...

San Antonio cancer biotech follows IPO with patent win in China

by Dale Harrison | Nov 2, 2022 | Articles, News

San Antonio cancer biotech follows IPO with patent win in China NOVEMBER 2, 2022 As published in the San Antonio Business Journal By: By W. Scott Bailey – Senior Reporter, San Antonio Business Journal The People’s Republic of China has awarded a Certificate of Patent...
« Older Entries
Next Entries »

Categories

  • Articles (28)
  • Events (38)
  • News (53)
  • Press Releases (142)
  • Publications (17)

Recent Posts

  • bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 October 7, 2025
  • bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering September 29, 2025
  • bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung September 26, 2025
  • bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025 September 17, 2025
  • Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules September 9, 2025
CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.